Supernus Pharmaceuticals, Inc.
SUPN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -12.25 | 2.65 | -0.50 |
| FCF Yield | 8.59% | 7.00% | 6.08% | 8.08% |
| EV / EBITDA | 10.98 | 17.16 | 14.72 | 13.67 |
| Quality | ||||
| ROIC | 5.69% | -0.25% | 4.73% | 4.53% |
| Gross Margin | 88.23% | 86.21% | 86.93% | 87.05% |
| Cash Conversion Ratio | 2.33 | 84.41 | 1.92 | 2.38 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.27% | 1.57% | 8.64% | 13.86% |
| Free Cash Flow Growth | 54.91% | -5.05% | -6.93% | -7.31% |
| Safety | ||||
| Net Debt / EBITDA | -0.20 | -0.37 | 2.25 | 1.68 |
| Interest Coverage | 0.00 | -2.18 | 9.52 | 3.67 |
| Efficiency | ||||
| Inventory Turnover | 1.43 | 1.08 | 0.95 | 0.87 |
| Cash Conversion Cycle | 311.24 | 415.30 | 429.49 | 466.38 |